IGM Biosciences, Inc. revenue for the last year amounted to 2.13 M USD, the most of which — 2.13 M USD — came from its highest performing source at the moment, Engineered Immunoglobulin M Antibodies, the year earlier bringing 1.07 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought IGM Biosciences, Inc. 2.13 M USD, and the year before that — 1.07 M USD.